REGN
HEALTHCARERegeneron Pharmaceuticals Inc
$721.05+18.78 (+2.67%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving REGN Today?
No stock-specific AI insight has been generated for REGN yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$474.60$820.12
$721.05
Fundamentals
Market Cap$75.6B
P/E Ratio17.6
EPS$40.96
Dividend Yield0.01%
Dividend / Share$3.58
ROE0.1%
Profit Margin0.3%
Debt / Equity—
Trading
Volume740K
Avg Volume (10D)—
Shares Outstanding103.0M
REGN News
50 articles- F m Investments LLC Has $17.61 Million Holdings in Regeneron Pharmaceuticals, Inc. $REGNMarketBeat·May 9, 2026
- Regeneron Pharma stock (US75886F1075): Biotech giant trades near $715 after modest gain on FridayAD HOC NEWS·May 9, 2026
- Assessing Regeneron (REGN) After Recent Share Price Weakness And Strong Valuation SignalsSimply Wall Street·May 8, 2026
- Giants of Cancer Care® announces the 14th annual class of inducteesYahoo Finance·May 8, 2026
- Gene Therapy Briefs: Regeneron Wins FDA Approval for First Neurosensory Gene TherapyGenetic Engineering and Biotechnology News·May 8, 2026
- Gene Therapy Briefs: Regeneron Wins FDA Approval for First Neurosensory Gene TherapyGenetic Engineering and Biotechnology News·May 8, 2026
- AbbVie’s Skyrizi beats out J&J’s Tremfya in in April drug ad spending leaderboardFierce Pharma·May 8, 2026
- Is It Time To Reassess Vertex (VRTX) After Recent Share Price Weakness?Simply Wall Street·May 8, 2026
- Only 8 biotech companies made this global responsibility index — Regeneron didStock Titan·May 8, 2026
- Regeneron Named to Dow Jones Best-in-Class World Index for Global Responsibility Leadership for Seven Consecutive YearsYahoo Finance·May 8, 2026
- Is This Biotech Stock a Buy After a Groundbreaking Approval?Motley Fool·May 8, 2026
- Lmcg Investments LLC Grows Holdings in Regeneron Pharmaceuticals, Inc. $REGNMarketBeat·May 7, 2026
- Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by K.J. Harrison & Partners IncMarketBeat·May 7, 2026
- Trump’s Affordability Push Stalls Ahead of Midterm ElectionsYahoo Finance·May 7, 2026
- Mitsubishi UFJ Asset Management Co. Ltd. Grows Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGNMarketBeat·May 7, 2026
- Bluebird Wealth Management LLC Makes New Investment in Regeneron Pharmaceuticals, Inc. $REGNMarketBeat·May 7, 2026
- RARE Q1 Loss Wider Than Expected, Sales Down Y/Y on Seasonal EffectYahoo Finance·May 6, 2026
- Medable CEO Michelle Longmire Featured as Guest Speaker with Leaders from Google and Mayo Clinic at Japan’s Largest Pharmaceutical SummitYahoo Finance·May 6, 2026
- Regeneron (REGN) Dupixent Phase 4 Trial Results Show Improved Esophageal Function in EoEAdvfn·May 5, 2026
- Zifo's SiEE Boston Summit Charts New Roadmap for 'Practical AI' in Life Sciences, Bridging the Gap Between Business Vision and Lab RealityYahoo Finance·May 5, 2026
- Dupixent® (dupilumab) Demonstrates Improved Esophageal Function in Eosinophilic Esophagitis (EoE) Phase 4 TrialYahoo Finance·May 5, 2026
- How The Regeneron (REGN) Narrative Is Shifting With Dupixent, Eylea And Pipeline DevelopmentsYahoo Finance·May 4, 2026
- 1 Cash-Producing Stock Worth Investigating and 2 Facing HeadwindsYahoo Finance·May 3, 2026
- Piper Sandler Rates Regeneron (REGN) Overweight on Oncology GrowthYahoo Finance·May 2, 2026
- Is Regeneron a Buy After the FDA Approved its Gene Therapy to Restore Hearing?Motley Fool·May 2, 2026
- Bristol Myers’ legacy lift, Biogen’s blue skies and Regeneron’s murky outlookBiopharmadive·May 1, 2026
- Regeneron's Eylea Franchise on 'Solid Footing' Despite HD Sales Miss in Q1, Oppenheimer SaysYahoo Finance·Apr 30, 2026
- Regeneron Q1 2026 net income falls 10% to $727mPharmaceutical-technology·Apr 30, 2026
- Regeneron Stock Tumbles on Earnings. Upcoming Data Matter More for the Stock.Yahoo Finance·Apr 29, 2026
- Regeneron Pharmaceuticals Q1 Earnings Call HighlightsMarketbeat·Apr 29, 2026
- Regeneron Slumps On An Unexpected Setback For Its Bread-And-Butter DrugYahoo Finance·Apr 29, 2026
- Regeneron Pharmaceuticals, Inc. Q1 2026 Earnings Call SummaryMoby·Apr 29, 2026
- FDA Approves First-Ever Gene Therapy for Treatment of Genetic Hearing Loss Under National Priority Voucher ProgramGlobeNewswire Inc.·Apr 24, 2026
- Regeneron Announces Agreement with U.S. Government to Help Lower Drug Costs for American Patients and Will Provide Innovative New Gene Therapy for Free in the U.S.GlobeNewswire Inc.·Apr 23, 2026
- Chronic Obstructive Pulmonary Disease Clinical Trial Landscape Expands: Over 65 Companies Advancing Next-Generation Therapies | DelveInsightGlobeNewswire Inc.·Apr 23, 2026
- Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticariaGlobeNewswire Inc.·Apr 22, 2026
- Communiqué de presse : Dupixent, développé par Sanofi et Regeneron, a été approuvé aux États-Unis comme étant le premier médicament biologique pour les jeunes enfants atteints d’urticaire chronique spontanée non contrôléeGlobeNewswire Inc.·Apr 22, 2026
- Bispecific Antibody Market Landscape Report 2026: A Potential $60 Opportunity by 2031 - Insight on More than 550 Clinical Trials - Antibody Dosage, Patent, Price, Sales & OutlookGlobeNewswire Inc.·Apr 21, 2026
- Non-Small Cell Lung Cancer Clinical Trial Race Intensifies as 100+ Companies Competing in Therapeutic Segment Worldwide | DelveInsightGlobeNewswire Inc.·Apr 16, 2026
- Generalized Myasthenia Gravis Market on the Brink of Change: 8 Promising Late-Stage Drugs Signal a New Treatment Era | DelveInsightGlobeNewswire Inc.·Apr 15, 2026
Price Data
Open$710.73
Previous Close$702.27
Day High$715.62
Day Low$699.23
52 Week High$820.12
52 Week Low$474.60
52-Week Range
$474.60$820.12
$721.05
Fundamentals
Market Cap$75.6B
P/E Ratio17.6
EPS$40.96
Dividend Yield0.01%
Dividend / Share$3.58
ROE0.1%
Profit Margin0.3%
Debt / Equity—
Trading
Volume740K
Avg Volume (10D)—
Shares Outstanding103.0M
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—